Nasdaq Inc (NDAQ)vsPfizer Inc (PFE)
NDAQ
Nasdaq Inc
$83.74
-0.64%
FINANCIAL SERVICES · Cap: $49.33B
PFE
Pfizer Inc
$27.28
+1.06%
HEALTHCARE · Cap: $153.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Pfizer Inc generates 1092% more annual revenue ($62.58B vs $5.25B). NDAQ leads profitability with a 34.1% profit margin vs 12.4%. NDAQ appears more attractively valued with a PEG of 2.10. NDAQ earns a higher WallStSmart Score of 69/100 (B-).
NDAQ
Strong Buy69
out of 100
Grade: B-
PFE
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+44.4%
Fair Value
$144.61
Current Price
$83.74
$60.87 discount
Margin of Safety
-194.9%
Fair Value
$9.25
Current Price
$27.28
$18.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 47.6%
Earnings expanding 47.6% YoY
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Generating 4.5B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Expensive relative to growth rate
Revenue declined 1.2%
Earnings declined 21.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : NDAQ
The strongest argument for NDAQ centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 34.1% and operating margin at 47.6%. Revenue growth of 13.4% demonstrates continued momentum.
Bull Case : PFE
The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.
Bear Case : NDAQ
The primary concerns for NDAQ are PEG Ratio, P/E Ratio.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
NDAQ profiles as a mature stock while PFE is a declining play — different risk/reward profiles.
NDAQ carries more volatility with a beta of 1.03 — expect wider price swings.
NDAQ is growing revenue faster at 13.4% — sustainability is the question.
PFE generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
NDAQ scores higher overall (69/100 vs 49/100), backed by strong 34.1% margins and 13.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nasdaq Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
Nasdaq, Inc. is an American multinational financial services corporation that owns and operates stock exchanges in the United States and Europe. It is headquartered in New York City.
Visit Website →Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Compare with Other FINANCIAL DATA & STOCK EXCHANGES Stocks
Want to dig deeper into these stocks?